About CareDx, Inc.
CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions
CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.
NASDAQ:CDNA
About AlloSure®
AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory.
http://www.allosure.com/
About AlloMap®
AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.
http://www.allomap.com/
|
|
|
11-50 employees
View all CareDx, Inc. employees
|
|
Biotechnology
|
|
8000 Marina Blvd, Brisbane, California 94005, US
|
|
Transplant Patient Care, Diagnostics And Transplant Patient Care, Diagnostics
|
CareDx, Inc. Alternatives
Frequently Asked Questions about CareDx, Inc.
Reginald Seeto is the CEO of CareDx, Inc.. To contact Reginald Seeto email at [email protected] or [email protected].
The decision makers in CareDx, Inc. are Anna Czene, Ashish Kothari, David Hummell, etc. Click to Find CareDx, Inc. decision makers emails.
CareDx specializes in non-invasive diagnostics for organ transplant patients. Their services include advanced surveillance management solutions that help monitor transplant health and detect potential complications early. This includes genomic testing, such as AlloSure, which assesses donor-derived cell-free DNA in the recipient's bloodstream to provide insights into transplant status.
The AlloSure test is a non-invasive blood test that measures the levels of donor-derived cell-free DNA (dd-cfDNA) in the recipient's bloodstream. Elevated levels of dd-cfDNA can indicate potential organ rejection or injury. This test allows healthcare providers to monitor transplant health without the need for invasive biopsies, enabling timely interventions when necessary.
CareDx supports a variety of organ transplants, including kidney, heart, and lung transplants. Their diagnostic solutions are designed to enhance patient care across these transplant types, providing healthcare professionals with the tools needed to monitor patient health effectively and improve long-term outcomes.
CareDx employs rigorous scientific methodologies and validation processes to ensure the accuracy and reliability of its diagnostic tests. The company collaborates with leading transplant centers and researchers to continuously refine their testing protocols and maintain high standards of quality control, ensuring that healthcare providers receive trustworthy data to guide patient care.
Yes, CareDx's solutions are designed to be easily integrated into existing healthcare systems. The company offers comprehensive support and training to healthcare providers to ensure seamless implementation. This integration allows for efficient data sharing and enhances the overall management of transplant patient care.
CareDx plays a crucial role in advancing transplant patient care by providing innovative diagnostic solutions that improve monitoring and management of transplant health. By utilizing non-invasive testing methods, CareDx helps healthcare providers make informed decisions, ultimately leading to better patient outcomes and quality of life for organ transplant recipients.
CareDx, Inc. Staff Directory
Search CareDx, Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
